'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Ankylosing Spondylitis (Bekhterev's Disease) 33
Mar 18, 2016: Celltrion Healthcare: Switching to Remsima (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies 33
Mar 16, 2016: Significantly higher persistence with SIMPONI (golimumab) in patients with rheumatic diseases compared with other subcutaneous TNF-alpha inhibitors, new study reveals 34
Clinical Trial Profile Snapshots 35
Appendix 216
Abbreviations 216
Definitions 216
Research Methodology 217
Secondary Research 217
About GlobalData 218
Contact Us 218
Disclaimer 218
Source 219
List of Tables
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 16
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 20
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Phase, 2016* 23
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 24
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 28
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32
List of Figures
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 15
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 19
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 23
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 24
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 28
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32
GlobalData Methodology 217